Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) saw a large increase in short interest during the month of December. As of December 30th, there was short interest totalling 73,600 shares, an increase of 429.5% from the December 15th total of 13,900 shares. Based on an average daily volume of 124,100 shares, the short-interest ratio is presently 0.6 days.
Bioasis Technologies Price Performance
Shares of BIOAF stock opened at $0.04 on Wednesday. The company has a 50 day moving average of $0.08 and a 200-day moving average of $0.11. Bioasis Technologies has a 12-month low of $0.02 and a 12-month high of $0.25. The firm has a market cap of $2.90 million, a P/E ratio of -0.91 and a beta of 0.40.
Get
Bioasis Technologies alerts:
Bioasis Technologies (OTCMKTS:BIOAF – Get Rating) last issued its quarterly earnings results on Friday, October 28th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.09 million for the quarter. As a group, equities analysts expect that Bioasis Technologies will post -0.03 EPS for the current year.
About Bioasis Technologies
(Get Rating)
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
Featured Articles
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
- Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
- Can Alaska Air Continue Soaring Above The Airline Industry?
- Insulet Has Potential To Gain More Than Analysts Are Forecasting
- Cathie Wood Is Buying These Stocks, Should You?
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
生物綠洲科技公司(BiOASIS Technologies Inc.)在12月份見證了空頭股數的大幅增長。截至12月30日，空頭股數共有73,600股，比12月15日的13,900股增加了429.5%。以日均成交量12.41萬股計算，目前短息比率為0.6天。
BiOASIS技術性價比
週三，BIOAF的股票開盤報0.04美元。該公司的50日移動均線切入位在0.08美元，200日移動均線切入位在0.11美元。BiOasis Technologies的12個月低點為0.02美元，12個月高位為0.25美元。該公司的市值為290萬美元，本益比為-0.91，貝塔係數為0.40。
到達
BiOASIS技術警報：
BiOasis Technologies(OTCMKTS：BIOAF-GET Rating)上一次發佈季度收益報告是在10月28日(星期五)。該公司公佈了該季度每股收益(EPS)(0.01美元)。該公司本季度的收入為90萬美元。作為一個整體，股票分析師預計BiOASIS Technologies本年度的每股收益將達到0.03歐元。
關於BiOASIS技術公司
(獲取評級)
BiOASIS技術公司是一家處於發展階段的生物製藥公司，致力於神經疾病和障礙的診斷和治療產品的研究和開發。它正在開發xB3，這是一種通過血腦屏障(BBB)運輸治療劑的平臺技術；以及治療中樞神經系統疾病(CNS)，包括腦癌，以及代謝和神經退行性疾病。
專題文章
- 免費獲取StockNews.com關於BiOASIS技術的研究報告(BIOAF)
- 人們對百事可樂的新蘇打水不感興趣，這有什麼關係嗎？
- 強生的突破：盈利能提振股市嗎？
- 阿拉斯加航空能否繼續在航空業之上高歌猛進？
- Insulet有潛力獲得超過分析師預測的收益
- 凱西·伍德正在購買這些股票，你應該這樣做嗎？
接受《BiOASIS技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對BiOasis Technologies及相關公司的評級的每日摘要。
